-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The World Health Organization estimates that chronic hepatitis B (CHB) affects 292 million people worldwide and kills nearly 900,000 people each year from complications of the disease.
chB is incurable and the antiviral drugs currently available can only control the disease and require lifelong treatment.
these treatments have a huge financial burden on CHB patients.
treatment, CHB can lead to serious health problems, including cirrhosis, liver failure and liver cancer.
in patients with chronic infections, high viral loads can induce immune tolerance, preventing T cells from removing the source of infection.
restoring T-cell function is thought to be critical to achieving a functional cure defined as the disappearance of surface antigens (HBsAg) of hepatitis B in the blood.
, the goal of the drug therapy is to reactivate the T-cell immune response.
biopharmaceutical company Altimmune announced today that it has included its first patient in HepTcell's Multi-Country Phase II clinical trial, a new peptide-based immunotherapy being developed to treat chronic hepatitis B (CHB).
the study, which is being conducted in the United States, Canada and Europe, was a double-blind, randomized, placebo-controlled study of 80 CHB patients.
end point is the virological response, defined as a decrease in HBsAg levels from the baseline at 24 weeks.
end points include reactivation of anti-HBV T cell responses, HBsAg removal rates, and other virological responses.
。